Skip to main content

Table 2 Patient characteristics in the case-control series: patients in the discovery cohort GWDb

From: Gene expression modules in primary breast cancers as risk factors for organotropic patterns of first metastatic spread: a case control study

  V cases V controls BV cases BV controls B cases B controls Case series
Number of patients 105 82 106 86 98 90 χ 2 p
Age at hist. diag. Median (years) 55.4 52.0 52.5 50.3 55.9 48.8   
Grade 1 3 (3%) 12 (15%) 3 (3%) 13 (15%) 8 (8%) 7 (8%)   
  2 27 (26%) 32 (39%) 44 (42%) 47 (55%) 44 (45%) 42 (47%)   
  3 68 (65%) 34 (41%) 55 (52%) 19 (22%) 38 (39%) 37 (41%)   
  Unknown 7 (7%) 4 (5%) 4 (4%) 7 (8%) 8 (8%) 4 (4%) 18.2 0.01
ER IHC status Positive 57 (54%) 52 (63%) 69 (65%) 62 (72%) 77 (79%) 65 (72%)   
  Negative 48 (46%) 30 (37%) 37 (35%) 24 (28%) 21 (21%) 25 (28%) 13.3 0.001
PR status Positive 39 (37%) 40 (49%) 53 (50%) 56 (65%) 59 (60%) 51 (57%)   
  Negative 66 (63%) 42 (51%) 53 (50%) 30 (35%) 39 (40%) 39 (43%) 10.9 0.004
HER2 status Positive 31 (30%) 13 (16%) 22 (21%) 13 (15%) 15 (15%) 11 (12%)   
  Negative 44 (42%) 38 (46%) 51 (48%) 41 (48%) 45 (46%) 42 (47%)   
  Unknown 30 (29%) 31 (38%) 33 (31%) 32 (37%) 38 (39%) 37 (41%) 7.0 0.1
Tumour size <= 2 cm 41 (39%) 39 (48%) 39 (37%) 44 (51%) 38 (39%) 47 (52%)   
  >2 cm 64 (61%) 42 (51%) 65 (61%) 38 (44%) 60 (61%) 41 (46%) 0.1 1.0
  Unknown -- -- 1 (1%) 2 (2%) 4 (5%) -- -- 2 (2%)   
Lymph nodes positive 0 15 (14%) 33 (40%) 21 (20%) 32 (37%) 24 (24%) 39 (43%)   
  1–3 34 (32%) 29 (35%) 31 (29%) 28 (33%) 30 (31%) 30 (33%)   
  4+ 37 (35%) 10 (12%) 40 (38%) 11 (13%) 26 (27%) 10 (11%)   
  Unknown 19 (18%) 10 (12%) 14 (13%) 15 (17%) 18 (18%) 11 (12%) 6.1 0.4
Invasive subtype NOS/no special type 96 (91%) 70 (85%) 85 (82%) 73 (85%) 82 (84%) 81 (90%)   
  Ductal - mucinous -- -- 2 (2%) 1 (1%) -- -- 1 (1%) 1 (1%)   
  Ductal - tubular -- -- -- -- 1 (1%) 3 (3%) 2 (2%) 1 (1%)   
  Ductal - other 1 (1%) 1 (1%) 1 (1%) -- -- -- -- 3 (3%)   
  Lobular - classical 5 (5%) 5 (6%) 7 (7%) 9 (10%) 12 (12%) 2 (2%)   
  Lobular - pleomorphic 1 (1%) 1 (1%) 6 (6%) -- -- -- -- 1 (1%)   
  Lobular - other -- -- 2 (2%) 2 (2%) 1 (1%) 1 (1%) -- --   
  Other 2 (2%) 1 (1%) 1 (1%) -- -- -- -- 1 (1%) 1.7 0.4 †
Surgery type (any time) Breast conserving 30 (29%) 34 (41%) 35 (33%) 43 (50%) 31 (32%) 39 (43%)   
  Breast conserving + mastectomy 17 (16%) 11 (13%) 19 (18%) 7 (8%) 15 (15%) 13 (14%)   
  Mastectomy 47 (45%) 33 (40%) 41 (39%) 30 (35%) 43 (44%) 35 (39%)   
  Unknown 11 (10%) 4 (5%) 11 (10%) 6 (7%) 9 (9%) 3 (3%) 1.2 1.0
Radiotherapy (adj/neo) Yes 79 (75%) 52 (63%) 84 (79%) 55 (64%) 82 (84%) 59 (66%)   
  No 26 (25%) 30 (37%) 22 (21%) 31 (36%) 16 (16%) 31 (34%) 2.2 0.3
Hormone treatment (adj/neo) Yes 84 (80%) 38 (46%) 97 (92%) 57 (66%) 92 (94%) 51 (57%)   
  No 21 (20%) 44 (54%) 9 (8%) 29 (34%) 6 (6%) 39 (43%) 11.0 0.004
Chemotherapy Neo-adj only -- -- 2 (2%) 2 (2%) 1 (1%) 5 (5%) 3 (3%)   
  Neo-adj and adj 4 (4%) -- -- 4 (4%) 1 (1%) 1 (1%) -- --   
  Adj only 65 (62%) 33 (40%) 67 (63%) 24 (28%) 43 (44%) 28 (31%)   
  No 36 (34%) 47 (57%) 33 (31%) 60 (70%) 49 (50%) 59 (66%) 8.7 0.01 ‡
Metastatic events in control series No mets, 64 (78%)
V = 8, BV = 8, B = 2
No mets, 66 (77%)
V = 10, BV = 5, B = 5
No mets, 69 (77%)
V = 4, BV = 10, B = 7
 
  1. †ductal versus lobular, ‡any versus no chemotherapy. Abbreviations as for Table 1